Payment overview · 2025
General Payments
$580.14
30 reported records · 12 companies
Healthcare provider profile · identity verified
Robert G Day, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, TN · NPI 1235120437
Verified facts
What the public records show
CMS Open Payments records show Robert G Day, MD received $580.14 in general payments during 2025 across 30 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $188.26 | 32.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.22 | 17.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.14 | 11.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.92 | 8.1% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.30 | 5.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.17 | 4.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.23 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.17 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.00 | 3.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $19.15 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.47 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.11 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $580.14 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $188.26 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.22 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.72 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $69.14 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.29 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 170 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 177 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 713 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 175 |
| Gabapentin | Gabapentin | 507 | 101 |
| Lisinopril | Lisinopril | 492 | 134 |
| Metformin Hcl | Metformin Hcl | 375 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 112 |
| Losartan Potassium | Losartan Potassium | 345 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 96 |
| Omeprazole | Omeprazole | 316 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 303 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 89 |
| Meloxicam | Meloxicam | 282 | 102 |
| Montelukast Sodium | Montelukast Sodium | 250 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 238 | 72 |
| Furosemide | Furosemide | 219 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 62 |
| Clonazepam | Clonazepam | 209 | 27 |
| Potassium Chloride | Potassium Chloride | 195 | 66 |
| Trazodone Hcl | Trazodone Hcl | 192 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 57 |
| Ozempic | Semaglutide | 177 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 176 | 51 |
| Jardiance | Empagliflozin | 170 | 40 |
| Eliquis | Apixaban | 163 | 42 |
| Famotidine | Famotidine | 153 | 42 |
| Alprazolam | Alprazolam | 149 | 31 |
| Tramadol Hcl | Tramadol Hcl | 137 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 42 |
| Allopurinol | Allopurinol | 129 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 125 | 64 |
| Azithromycin | Azithromycin | 122 | 104 |
| Carvedilol | Carvedilol | 122 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 25 |
| Simvastatin | Simvastatin | 118 | 35 |
| Buspirone Hcl | Buspirone Hcl | 112 | 35 |
| Glimepiride | Glimepiride | 109 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 31 |
| Farxiga | Dapagliflozin Propanediol | 103 | 20 |
| Bupropion Xl | Bupropion Hcl | 96 | 24 |
| Donepezil Hcl | Donepezil Hcl | 96 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 91 | 21 |
| Januvia | Sitagliptin Phosphate | 91 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 25 |
| Metformin Hcl Er | Metformin Hcl | 79 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 18 |
| Spironolactone | Spironolactone | 78 | 26 |
| Methylprednisolone | Methylprednisolone | 77 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 22 |
| Prednisone | Prednisone | 76 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 18 |
| Baclofen | Baclofen | 66 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 62 | 16 |
| Sertraline Hcl | Sertraline Hcl | 62 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 53 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 19 |
| Pregabalin | Pregabalin | 59 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Mirtazapine | Mirtazapine | 56 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Lorazepam | Lorazepam | 55 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 11 |
| Linzess | Linaclotide | 53 | 21 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 11 |
| Trulicity | Dulaglutide | 52 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 17 |
| Synthroid | Levothyroxine Sodium | 51 | 15 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Testosterone | Testosterone | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Primidone | Primidone | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Atenolol | Atenolol | 34 | 11 |
| Cephalexin | Cephalexin | 34 | 32 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 15 |
| Metolazone | Metolazone | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 19 |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 16 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 14 |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $580.14 · 30 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, BREZTRI, CAPLYTA, FARXIGA, GEMTESA, JARDIANCE, MOUNJARO, NURTEC ODT, Natroba, Ohtuvayre, Ozempic, Rybelsus, SHINGRIX, Spinosad, The Cologuard Plus Collection Kit, VOQUEZNA, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error